Pharmaceutical Technology

AUGUST 30, 2022

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

Development 130

Development Drugs Bioavailability Production 130

Pharmaceutical Technology

JANUARY 23, 2023

As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m

Marketing 278

Marketing Production Drugs Trials 278

Bio Pharma Dive

AUGUST 25, 2023

Neumora’s filing late Friday, along with that of radiopharmaceutical startup RayzeBio earlier this week, could be an important test of the biotech IPO market.

Development 246

Development Drugs Marketing 246

Pharmaceutical Technology

JUNE 12, 2023

Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia. Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.

Marketing 242

Marketing Production Branding Manufacturing 242

Pharmaceutical Technology

NOVEMBER 3, 2022

Emalex Biosciences has raised Series D funds worth $250m led by Bain Capital Life Sciences to progress the development of an investigational new drug for Tourette syndrome. In prior trials, the drug was found to be well tolerated. Tourette syndrome is a serious ailment of CNS.

Development 130

Development Drugs Clinical Trials Clinical Trials 130

Pharmaceutical Technology

APRIL 5, 2023

PRIME is an EMA scheme to support the development of medicines for rare diseases and conditions with high unmet need. The scheme also supported the development of thirteen treatments across several therapy areas last year. Breyanzi is a treatment for various lymphomas and Carvykti is an orphan medicine for multiple myeloma.

Development 130

Development Drugs Medicine Production 130

Pharmaceutical Technology

AUGUST 15, 2023

A deep understanding of regional differences in regulations and marketing is critical for global launches.

Packaging 130

Packaging Packaging Marketing Regulation 130

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). As per the terms of the agreement, LegoChem will receive up to $1.25bn in upfront, development and commercial milestone payments from Amgen.

Antibody 130

Antibody Development Drugs Licensing 130

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). Astellas and Sutro will expedite the development of iADCs for three different biological targets.

Development 264

Development Antibody Immune Response Production 264

Pharmaceutical Technology

JUNE 15, 2023

The need for new medical treatments and drugs has never been greater. But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Pharmaceutical Technology

AUGUST 29, 2022

Sanyou Biopharmaceuticals and Shanghai KangaBio have signed a licencing agreement to expedite the development and innovation of the former’s monoclonal antibody drug. Sanyou and KangaBio will join forces to offer new prodrug development for immunotherapy based on their expertise and industry resources.

Antibody 130

Antibody Development Drugs Production 130

Drug Discovery World

FEBRUARY 26, 2024

The global ADME toxicology testing market is predicted to generate a revenue of $19.21 Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.

Marketing 59

Marketing Drugs Development 59

Bio Pharma Dive

FEBRUARY 23, 2023

Sanofi and its development partner, Sobi, claim the drug’s once-a-week dosing, and its effect on blood-clotting protein levels, will help it compete in the crowded market for hemophilia A treatments.

FDA Approval 273

FDA Approval Drugs Protein Marketing 273

Pharmaceutical Technology

NOVEMBER 1, 2022

What is Research and Development (R&D)? This category includes organisations that have demonstrated a commitment to the research and development of new products and/or new processes. This category highlights companies that have conducted research into the use of AI and technology for the development of new treatments.

Development 228

Development Research Production Vaccination 228

XTalks

JANUARY 16, 2024

To date, the lack of objective longitudinal measures in central nervous system (CNS) clinical studies has resulted in less than 6 percent of drugs in this space making it to market. CJ Barnum, PhD, Vice President of CNS Development, INmune Bio, Inc. about various aspects of CNS drug development.

Development 122

Development Drugs Clinical Trials Clinical Trials 122

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer.

Development 264

Development Hormones Production Marketing 264

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

Development 59

Development Drugs Genome Genomics 59

World of DTC Marketing

APRIL 21, 2022

I can get better results using digital laser targeting and targeted print ads, but DTC marketers are like TV because it makes them feel important within their company. ” Marketers were tapped to develop a model that showed the patient’s journey to getting an Rx. The post DTC marketers addicted to TV.

Marketing 227

Marketing Branding Drugs Development 227

Pharmaceutical Technology

FEBRUARY 13, 2023

SOPHiA GENETICS is expanding its collaboration with AstraZeneca to include multimodal approaches for developing cancer drugs. They will also support evidence generation for market access and help clinicians choose the best possible treatments.

Genetics 130

Genetics Development Drugs Genome 130

World of DTC Marketing

APRIL 22, 2021

QUICK READ: More TV DTC spots are airing, but DTC marketers are losing the battle between awareness and conversion because of all the noise online. I’ve spent the last six months analyzing clients’ DTC marketing campaigns and they are, for most ineffective.

Marketing 265

Marketing Doctors Doctor Branding 265

Pharmaceutical Technology

SEPTEMBER 23, 2022

While a handful of therapies have launched since then, late-stage pipeline therapies that are currently in development reveal that drug developers are exploring a broad set of mechanisms of action (MOAs), many of which are innovative, to tackle DES. Novaliq’s CyclASol (0.1%

Development 147

Development Drugs Clinical Trials Clinical Trials 147

Pharmaceutical Technology

FEBRUARY 9, 2023

The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients.

Development 241

Development RNA Gene Therapy Genetics 241

World of DTC Marketing

JANUARY 26, 2022

This is an exciting time to be in healthcare marketing. We’re witnessing the most significant transformation in healthcare marketing since DTC was approved in the ’90s. is no more an option but the critical factor to ensure success for any multichannel marketing initiatives.

Marketing 202

Marketing Pharma Companies Production Drugs 202

Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. There are currently over 700 immuno-oncology products in Phase I-III of development in the eight major markets, said Chalk.

Marketing 264

Marketing Vaccination Vaccine Development 264

Pharmaceutical Technology

FEBRUARY 16, 2023

The University of Texas MD Anderson Cancer Center has entered a strategic collaboration with biotech company Xilis for advancing new technology and expediting new cancer therapy development. Under the deal, MD Anderson and Xilis aim to advance the development of drug and discovery projects using the MOS technology.

Development 242

Development Gene Therapy Gene Drugs 242

Drug Discovery World

FEBRUARY 19, 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. antibody-drug conjugate [ADC] pipelines in some oncology settings).

Development 59

Development Gene Therapy Drugs Antibody 59

Pharmaceutical Technology

NOVEMBER 16, 2022

Clinical-stage biopharmaceutical companies NextCure and LegoChem Biosciences have signed a collaboration and co-development agreement to develop a B7-H4 antibody drug conjugate (ADC), and features options for two further targets. Furthermore, NextCure signed a supply agreement for Keytruda with Merck.

Antibody 130

Antibody Development Drugs Production 130

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Antibody 98

Antibody Marketing Drugs Licensing 98

Drug Discovery World

FEBRUARY 20, 2024

The drug discovery informatics market is predicted to grow from $3.77 The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.

Marketing 52

Marketing Drugs Life Science Genome 52

Pharmaceutical Technology

DECEMBER 15, 2022

Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments. Under the deal, the parties intend to develop treatments for diseases including Alzheimer’s and Parkinson’s.

Development 246

Development Medicine Sales Scientist 246

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

Development 52

Development Drugs Genome Genomics 52

BioSpace

APRIL 14, 2024

GLP-1 treatments are all the rage in this space, but they aren’t the only approach in development. The pipeline assets highlighted here offer a differentiated approach, potentially increasing efficacy or reducing side effects.

Marketing 132

Marketing Drugs Development 132

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Pharmaceutical Technology

JANUARY 22, 2024

Obesity drugs are in such high demand in developed markets that there is a shortage of Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Mounjaro and Trulicity,

Drugs 130

Drugs Marketing Development 130

World of DTC Marketing

APRIL 19, 2022

Before most drugs are launched, much time and effort are spent developing marketing plans and getting approval. However, given the rapid changes in the market and the realization that too many tactics are more hype than reality, fixed marketing plans are a waste of time. As times change, so do trends.

Marketing 192

Marketing Branding Production Development 192

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Manufacturing Process : Small Molecules: Manufactured through chemical synthesis, small molecule drugs can be consistently reproduced with a high degree of purity and stability.

Development 77

Development Drugs Manufacturing Immune Response 77

World of DTC Marketing

MARCH 9, 2021

SUMMARY : DTC marketers are spending tens of millions of dollars on programmatic ads that are full of fraud and have low click-through rates but they have yet to embrace email marketing which has an average click-through rate of 3.43%. The key to effective email marketing is segmentation and personalization.

Marketing 289

Marketing Branding Packaging Packaging 289